These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35101281)

  • 61. Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.
    Rouamba T; Ouédraogo E; Barry H; Yaméogo NV; Sondo A; Boly R; Zoungrana J; Ouédraogo AR; Tahita MC; Poda A; Diendéré AE; Ouedraogo AS; Valea I; Traoré I; Tarnagda Z; Drabo MK; Tinto H;
    Int J Infect Dis; 2022 May; 118():224-229. PubMed ID: 35227869
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
    Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
    Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
    Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
    Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
    Jung SY; Kim MS; Kim MC; Choi SH; Chung JW; Choi ST
    Clin Microbiol Infect; 2021 Apr; 27(4):611-617. PubMed ID: 33316402
    [TBL] [Abstract][Full Text] [Related]  

  • 65. No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19.
    Sands K; Wenzel R; McLean L; Korwek K; Roach J; Miller K; Poland RE; Burgess LH; Jackson E; Perlin JB
    Int J Infect Dis; 2021 Mar; 104():34-40. PubMed ID: 33359949
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.
    In 't Veld AE; Jansen MAA; Ciere LCA; Moerland M
    J Immunol Res; 2021; 2021():6659410. PubMed ID: 33763494
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy.
    Spila Alegiani S; Crisafulli S; Giorgi Rossi P; Mancuso P; Salvarani C; Atzeni F; Gini R; Kirchmayer U; Belleudi V; Kurotschka PK; Leoni O; Ludergnani M; Ferroni E; Baracco S; Massari M; Trifirò G;
    Rheumatology (Oxford); 2021 Oct; 60(SI):SI25-SI36. PubMed ID: 33856453
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
    Nicolò M; Ferro Desideri L; Bassetti M; Traverso CE
    Int Ophthalmol; 2021 Feb; 41(2):719-725. PubMed ID: 32946004
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
    Million M; Lagier JC; Gautret P; Colson P; Fournier PE; Amrane S; Hocquart M; Mailhe M; Esteves-Vieira V; Doudier B; Aubry C; Correard F; Giraud-Gatineau A; Roussel Y; Berenger C; Cassir N; Seng P; Zandotti C; Dhiver C; Ravaux I; Tomei C; Eldin C; Tissot-Dupont H; Honoré S; Stein A; Jacquier A; Deharo JC; Chabrière E; Levasseur A; Fenollar F; Rolain JM; Obadia Y; Brouqui P; Drancourt M; La Scola B; Parola P; Raoult D
    Travel Med Infect Dis; 2020; 35():101738. PubMed ID: 32387409
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials.
    Chi G; Memar Montazerin S; Lee JJ; Kazmi SHA; Shojaei F; Fitzgerald C; Gibson CM
    J Med Virol; 2021 Dec; 93(12):6737-6749. PubMed ID: 34370328
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?
    Pothen L; Yildiz H; Samnick MM; Yombi JC
    Clin Rheumatol; 2021 Apr; 40(4):1649-1657. PubMed ID: 33452660
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19.
    Sattui SE; Liew JW; Graef ER; Coler-Reilly A; Berenbaum F; Duarte-García A; Harrison C; Konig MF; Korsten P; Putman MS; Robinson PC; Sirotich E; Ugarte-Gil MF; Webb K; Young KJ; Kim AHJ; Sparks JA
    Expert Rev Clin Immunol; 2020 Jul; 16(7):659-666. PubMed ID: 32620062
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
    Hernandez AV; Roman YM; Pasupuleti V; Barboza JJ; White CM
    Ann Intern Med; 2020 Aug; 173(4):287-296. PubMed ID: 32459529
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Knowing more about chloroquine/hydroxycloroquine in COVID-19 patients.
    Cassone A; Iacoviello L; Cauda R
    Future Microbiol; 2020 Oct; 15():1523-1526. PubMed ID: 33206554
    [No Abstract]   [Full Text] [Related]  

  • 75. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
    Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
    Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue.
    Ward JK; Alleaume C; Peretti-Watel P;
    Soc Sci Med; 2020 Nov; 265():113414. PubMed ID: 33038683
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chloroquine and COVID-19-A systems biology model uncovers the drug's detrimental effect on autophagy and explains its failure.
    Kapuy O; Korcsmáros T
    PLoS One; 2022; 17(4):e0266337. PubMed ID: 35390060
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Many trials of hydroxychloroquine for SARS-CoV-2 were redundant and potentially unethical: an analysis of the NIH clinical trials registry.
    Yogendrakumar V; Dewar B; McGuinty M; Dowlatshahi D; Dyason C; Kwok ES; Ramsay T; Lund H; Shamy M
    J Clin Epidemiol; 2022 Mar; 143():73-80. PubMed ID: 34780978
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19.
    Manivannan E; Karthikeyan C; Moorthy NSHN; Chaturvedi SC
    Front Pharmacol; 2021; 12():584940. PubMed ID: 34025393
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
    Fiolet T; Guihur A; Rebeaud ME; Mulot M; Peiffer-Smadja N; Mahamat-Saleh Y
    Clin Microbiol Infect; 2021 Jan; 27(1):19-27. PubMed ID: 32860962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.